Grifols SA
GRFS
View Detailed Chart
7.520USD
-0.190-2.46%
Market hours （ET）Quotes delayed by 15 min
1.94BMarket Cap
11.29P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.46%
5 Days
-3.22%
1 Month
-16.07%
6 Months
-23.42%
Year to Date
-19.57%
1 Year
+0.80%
View Detailed Chart
TradingKey Stock Score of Grifols SA
Currency: USD Updated: 2026-03-26Key Insights
Grifols SA's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.20.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Grifols SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Grifols SA Highlights
StrengthsRisks
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.48B.
Undervalued
The company’s latest PE is 11.44, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 144.63M shares, decreasing 11.83% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.94K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
12.200
Target Price
+60.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Grifols SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Grifols SA Info
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Ticker SymbolGRFS
CompanyGrifols SA
CEOAbia (Jose Ignacio)
Websitehttps://www.grifols.com/
Related Instruments
-2.66%
-0.83%
+0.80%
+1.85%
+1.13%
+0.54%
0.00%
-0.13%
-2.28%
-0.76%
-0.37%
+2.95%
-0.18%
+0.42%
-1.72%
0.00%
-0.81%
-2.26%
-1.66%
-0.85%Popular Symbols
252.530
-0.360 (-0.14%)
169.025
-2.215 (-1.29%)
66330.880
-2644.330 (-3.83%)
275.365
+2.015 (+0.74%)
1998.440
-63.950 (-3.10%)
365.675
-6.435 (-1.73%)
4532.480
+152.420 (+3.48%)
96.999
+3.677 (+3.94%)
1.154
+0.001 (+0.11%)
159.777
-0.010 (-0.01%)
